Previous studies have suggested that marijuana (cannabis sativa) and delta-9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient of marijuana, are effective in the therapy of tics and associated behavioral disorders in Tourette Syndrome (TS). Because there is also evidence that cannabis sativa may cause cognitive impairment in healthy users, we performed a randomized double-blind placebo-controlled crossover trial for Δ9-THC in 12 adult TS patients to investigate whether treatment of TS with a single dose of Δ9-THC at 5.0 to 10.0 mg causes significant side effects on neuropsychological performance. Using a variety of neuropsychological tests, we found no significant differences after treatment with Δ9-THC compared to placebo treatment in verbal and visual memory, reaction time, intelligence, sustained attention, divided attention, vigilance, or mood. Only when using the Symptom Checklist 90-R (SCL-90-R) did our data provide evidence for a deterioration of obsessive-compulsive behavior (OCB) and a trend towards an increase in phobic anxiety. However, these results should be interpreted with caution as SCL-90-R has known limitations on measuring OCB. We suggest that the increase in phobic anxiety is mainly due to the fact that a single-dose treatment rules out the possibility of administering the dosage slowly. In contrast to results obtained from healthy marijuana users, a single-dose treatment with Δ9-THC in patients suffering from TS does not cause cognitive impairment. We therefore suggest that further investigations should concentrate on the effects of a longer-term therapy of TS with Δ9-THC.
3
Block R I, Farinpour R, Braverman K.
Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques.
Pharmacol Biochem Behav.
1992;
43
907-917
6
Chan P K, Chan S C, Yung W H.
Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurons by cannabinoid agonist.
Neuroreport.
1998;
9
671-675
8 Comings D E, Comings B G. Comorbid behavioral disorders. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc. 1993: 111-147
9
Consroe P, Musty R, Rein J, Tillery W, Pertwee R.
The perceived effects of smoked cannabis on patients with multiple sclerosis.
Eur Neurol.
1997;
38
44-48
11
Crawley J N, Corwin R L, Robinson J K, Felder C C, Devane W A, Axelrod J.
Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents.
Pharmacol Biochem Behav.
1993;
46
967-972
13 Derogatis L R. SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine 1977
14
Devane W A, Hanus L, Breuer A, Pertwee R G, Stevenson L A, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R.
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Science.
1992;
258
1946-1949
15
Emrich H M, Leweke F M, Schneider U.
Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.
Pharmacol Biochem Behav.
1997;
56
803-807
16
Gessa G L, Melis M, Muntoni A L, Diana M.
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.
Eur J Pharmacol.
1998;
341
39-44
18
Gorriti M A, Rodriguez de Fonseca F, Navarro M, Palomo T.
Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.
Eur J Pharmacol.
1999;
365
133-142
19 Grotenhermen F, Karus M. Marihuana: Die rechtliche Situation in Deutschland. Der Stand der medizinischen Forschung. In Marihuana, die verbotene Medizin. Zweitausendeins, Frankfurt am Main 1994 1. Aufl: 211-272
25
Herkenham M, Lynn A B, Little M D, Johnson M R, Melvin L S, de Costa B R, Rice K C.
Cannabinoid receptor localization in brain.
Proc Natl Acad Sci USA.
1990;
87
1932-1936
28
Jentsch J D, Andrusiak E, Tran A, Bowers M B, Roth R H.
Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966.
Neuropsychopharmacology.
1997;
16
426-432
29
Johannes S, Weber A, Müller-Vahl K R, Kolbe H, Dengler R, Münte T F.
Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette syndrome.
Eur J Neurology.
1997;
4
152-161
30
Kim S W, Dysken M W, Kuskowski M.
The Symptom Checklist-90: Obsessive-Compulsive Subscale: A reliability and validity study.
Psychiatry Res.
1992;
41
37-44
33 Korzyn A D. Future therapies. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc 1993: 199-220
34 Leckman J F, Towbin K E, Ort S I, Cohen D J. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF Tourette Syndrome and tic disorders. New York; John Wiley 1988: 55-78
35
Mailleux P, Vanderhaeghen J-J.
Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons.
Neurosci Lett.
1992;
148
173-176
36
Maneuf Y P, Nash J E, Crossman A R, Brotchie J M.
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
Eur J Pharmacol.
1996;
308
161-164
37 Marsden C D. Treatment of torsion dystonia. Barbeau, A. (ed.) Disorders of Movement. Current status of modern therapy. Philadelphia; Lippincott 1981 8: 81-104
39
Miller A S, Sanudo-Pena M C, Walker J M.
Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus.
Brain Res.
1998;
793
7-11
40
Miller A S, Walker J M.
Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata.
Eur J Pharmacol.
1995;
279
179-185
41
Molina-Holgado F, Amaro A, Gonzalez M I, Alvarez F J, Leret M L.
Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system.
Eur J Pharmacol.
1996;
316
39-42
42
Müller-Vahl K R, Kolbe H, Schneider U, Emrich H M.
Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome.
Acta Psychiat Scand.
1998;
98
502-506
43 Müller-Vahl K R, Schneider U, Koblenz A, Jöbges M, Kolbe H, Dahltrup T, Emrich H M. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol (THC): a randomized crossover trial. (submitted)
44
Müller-Vahl K R, Schneider U, Kolbe H, Emrich H M.
Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol.
Am J Psychiatry.
1999;
156
495
45
Palumbo D, Maughan A, Kurlan R.
Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome.
Arch Neurol.
1997;
54
475-483
46
Pope H G, Gruber A J, Yurgelun-Todd D.
The residual neuropsychological effects of cannabis: the current status of research.
Drug Alcohol Depend.
1995;
38
25-34
50
Sanudo-Pena M C, Walker J M.
Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat.
J Neurophysiol.
1997;
77
1635-1638
51
Schneider U, Leweke F M, Müller-Vahl K R, Emrich H M.
Cannabinoid/anandamide system and schizophrenia: is there evidence for association?.
Pharmacopsychiatry.
1998;
31
(Suppl. 2)
110-113
52
Schwartz R H, Gruenewald P J, Klitzner M, Fedio P.
Short-term memory impairment in cannabis-dependent adolescents.
Am J Dis Child.
1989;
143
1214-1219
54
Shen M, Piser T M, Seybold V S, Thayer S A.
Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.
J Neurosci.
1996;
16
4322-4334
55
Shen M, Thayer S A.
Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.
Mol Pharmacol.
1999;
55
8-13
56
Sieradzan K A, Fox S H, Dick J, Brotchie J M.
The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD).
Mov Disord.
1998;
13
(Suppl. 2)
29
57
Solowij N, Michie P T, Fox A M.
Differential impairments of selective attention due to frequency and duration of cannabis use.
Biol Psychiatry.
1995;
37
731-739
58
Swets J A, Green D M, Getty D J, Swets J B.
Signal detection and identification at successive stages of observation.
Percept Psychopsy.
1978;
23
275-289
63
Woody S R, Steketee G, Chambless D L.
The usefulness of the Obsessive Compulsive Scale of the Symptom Checklist-90-Revised.
Behav Res Ther.
1995;
33
607-611
64
Yordanova J, Dumais-Huber C, Rothenberger A, Woerner W.
Frontocortical activity in children with comorbidity of tic disorder and attention-deficit hyperactivity disorder.
Biol Psychiatry.
1997;
41
585-594
65
Ziemann U, Paulus W, Rothenberger A.
Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation.
Am J Psychiatry.
1997;
154
1277-1284
66 Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg 1989